Keyword Search
Free Preview
Login    Register   

Login to your account

No Account Yet? Fields marked with an asterisk (*) are required.

Please enter a valid Username. No spaces, at least 2 characters and must contain only letters and numbers.
Please enter a valid Password. No spaces, at least 4 characters and must contain only letters and numbers.
Passwords do not match.
Please enter a valid e-mail address.
E-mails do not match. ?>


By purchasing an article in PDF format, you are agreeing to follow our Article Policy.

Use the "Buy Now" button to purchase an article.  Once checkout is complete, a download link will be sent to the email address that you provide during checkout.


Use the KEYWORD search located in the top left column to look for keywords, authors, and titles. If you still can't find what you're looking for, please This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Design and Optimization of a Purification Process for MY32/Ls Protein Solubilizing Inclusion Bodies for a New Vaccine Against Sea Lice

by Carlos Perez Heredia, Nemecio González Fernández, Eladio Salazar Gómez, Eulogio Pimentel Vázquez, Yamila Carpio González, and Miladys Limonta Fernández
Volume 14, Issue 1 (Spring 2015)

Sea lice are the most problematic marine pathogens the salmon industry has to deal with, significantly affecting Europe and America. The worst offenders are genera: Pseudocaligus, Caligus, and Lepeophtheirus. Over €305 million in losses are estimated. Recent results have suggested that subolesin/akirin/myosin32 are good candidate antigens for the control of arthropod infestations such as sea lice. The aim of this study was to design and optimize the purification step of MY32/Ls protein to obtain the active pharmaceutical ingredient against sea lice. Non-chromatographic purification strategies were employed, based on published works, to establish rupture, washing, solubilization, and refolding conditions...

Citation:
Heredia CP, Fernández NG, Gómez ES, Vázquez EP, González YC, Fernández ML. Design and optimization of a purification process for MY32/Ls protein solubilizing inclusion bodies for a new vaccine against sea lice. BioProcess J, 2015; 14(1): 49–59. http://dx.doi.org/10.12665/J141.Heredia.

Posted online May 1, 2015.

 
Two-Step Purification of Antibody from Tobacco Plants for Vaccine Manufacturing: Aqueous Two-Phase Extraction and Affinity Chromatography

by Williams Ferro, Tatiana Álvarez, Déborah Geada, Yenisley Medina, Yarysel Guevara, José Montero, Andrés Tamayo, Ariadna López, Daily Hernández, Mayra Wood, Tatiana González, Regla Somoza, and Rodolfo Valdés
Volume 14, Issue 1 (Spring 2015)

The purification of PHB-01 plantibody derived from tobacco leaves imposed difficulties when the plantibody solid-liquid extraction design was performed. Thus, our study focused on assessing a combination of an aqueous two-phase extraction (ATPE) procedure and affinity chromatography for solving some of the issues in plantibody purification. This was done using a complete factorial redesign, different polyethylene glycol (PEG)/K2PO4 proportions, and pH values in each partitioning variant. Out of the results of 27 variants, ten were selected for the subsequent purification step, considering an antibody recovery of ≥ 80% and a leaf-soluble protein removal capacity of ≥ 30%. Regarding this, the best ATPE combination was PEG 6000 (20%)/K2PO4 (10%), pH 5.5, showing 95.44 ± 7.89% of antibody recovery and 32.86 ± 17.02% of leaf-soluble protein removal capacity. Besides, the organoleptic properties of ATPE preparation were similar to those observed in solid-liquid extraction preparation, but a reduction in operation unit number and bioprocessing time was demonstrated. Next, the antibody extracted in the three of ten selected variants was submitted to affinity chromatography for increasing molecule recovery and purity. The highest recovery was measured in PEG 4000 (10%)/K2PO4 (15%), pH 5.5, (92.69 ± 4.81%). Conversely, a significant decrease in antibody recovery (p = 0.000) was observed when antibody was purified after ATPE with PEG 6000 (ranging from 54.81 ± 17.05% to 65.37 ± 13.47%). The antibody electrophoretic mobility was unmodified by the addition of PEG in ATPE, and antibody purity measured by SDS-PAGE did not show significant differences (> 97%). These preliminary results allowed us to predict that a combination of ATPE and affinity chromatography could be useful for solving issues in industrial-scale PHB-01 purification...

Citation:
Ferro W et al. Two-step purification of antibody from tobacco plants for vaccine manufacturing: aqueous two-phase extraction and affinity chromatography. BioProcess J, 2015; 14(1): 43–8. http://dx.doi.org/10.12665/J141.Valdes.

Posted online May 1, 2015.

 
Virotherapy Process Optimization

by Michael Artinger, PhD
Volume 14, Issue 1 (Spring 2015)

An emerging application of viruses involves engineering them to treat diseases using a number of approaches. Broadly defined under the “virotherapy” umbrella, these include viral vectors used for gene therapy, oncolytic viruses, and viral immunotherapy. Although a majority of these products are in various stages of clinical development, the diversity of the therapeutic targets and wealth of future opportunities is encouraging. A significant challenge, as it is for any virus-based technology, is gaining a clear picture of the quality of a sample at any given point—from early research and development through manufacturing and product release. Of prime concern is the quantification of viruses, which in the past, has relied on slow, labor-intensive, subjective methods such as plaque titer assays and electron microscopic imaging. However, the diversity of new viral technologies now being used as the basis for innovative drugs and vaccines requires advanced, sophisticated analytical systems. In this white paper, we discuss how the real-time enumeration of viruses made possible by the ViroCyt® Virus Counter® 3100 can significantly enhance the pace of virotherapy product development...

Citation:
Artinger M. Virotherapy process optimization. BioProcess J, 2015; 14(1): 26–9. http://dx.doi.org/10.12665/J141.Artinger.

Posted online May 1, 2015.

 
Successful High Density Escherichia coli Fermentation Using the Eppendorf BioFlo® 320 Advanced Bioprocess Control System

by Bin Li, PhD and Ma Sha, PhD
Volume 14, Issue 1 (Spring 2015)

The gram-negative bacterium, Escherichia coli, has a long history in the world of laboratory and industrial processes due to its ease of manipulation and well-understood genome. It is widely cultured under aerobic conditions. High cell density cultivation of E. coli is a powerful technique for the production of recombinant proteins. Indeed, 30% of the FDA-approved biopharmaceuticals on the market are produced in E. coli. An Escherichia coli fermentation run conducted using the Eppendorf BioFlo® 320 bioprocess control station achieved high cell density at 12 hours, as determined by a maximum optical density (OD600) measurement of 215.2. The weights of dry and wet cells were also measured...

Citation:
Li B, Sha M. Successful high density Escherichia coli fermentation using the Eppendorf BioFlo® 320 advanced bioprocess control system. BioProcess J, 2015; 14(1): 20–4. http://dx.doi.org/10.12665/J141.LiSha.

Posted online May 1, 2015.

 
Continued Process Verification: Monitoring and Maintaining a State of Control

by Kate Lusczakoski, PhD
Volume 14, Issue 1 (Spring 2015)

To ensure that a commercial biomanufacturing process is in a state of control, life science companies must create and successfully execute initiatives to meet continued process verification (CPV) and other monitoring guidelines. Management at pharmaceutical, biotech, and medical device companies commonly receive directives associated with data monitoring. Various challenges arise in the development and maintenance of a successful global monitoring program. Because of this, many companies develop data monitoring programs that are not scalable and sustainable. Company leaders struggle with how best to adopt, deploy, and scale monitoring systems to achieve defined quality monitoring goals. The purpose of this article is to display a maturity model to help companies navigate the major steps of implementing a global monitoring plan for continued process verification.

Citation:
Lusczakoski K. Continued process verification: monitoring and maintaining a state of control. BioProcess J, 2015; 14(1): 36–42. http://dx.doi.org/10.12665/J141.Lusczakoski.

Posted online April 29, 2015.

 
Using Product Lifecycle, Process Validation, and Quality by Design (QbD) Paradigms to Efficiently Take New Biopharmaceutical Products from Pre-IND to Commercial Manufacturing

by Mark F. Witcher, PhD
Volume 14, Issue 1 (Spring 2015)

This paper describes how a biopharmaceutical product development effort can be structured to identify, understand, and plan activities and goals required to efficiently and rapidly deliver new products and therapies to patients. Although the paper focuses on manufacturing, the approach can be used for all aspects of pharmaceutical product development from establishing an intellectual property position, developing a comprehensive manufacturing plan, to creating a marketing program.

Citation:
Witcher MF. Using product lifecycle, process validation, and quality by design (QbD) paradigms to efficiently take new biopharmaceutical products from pre-IND to commercial manufacturing. BioProcess J, 2015; 14(1): 30–5. http://dx.doi.org/10.12665/J141.Witcher.

Posted online April 15, 2015.

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Endorsed Events
Please update your Flash Player to view content.
Please update your Flash Player to view content.
Please update your Flash Player to view content.